Replies to post #310 on Bluebird Bio Inc (BLUE)

[Moose412]

I expect to see another class-action investigation by Pomerantz, but it won't go anywhere. It's not deserved.

But given the profile of this race, it's absurd that the FDA would do this.

No reason trading shouldn't be at $5, with all three drugs. The lack of PRV is mind-boggling, given the indication of 12 yrs+. Monday is going to be interesting.